-Reuters
The FDA Has Completed A Filing Review Of Valneva’s Biologics License Application For Its Single-shot Chikungunya Vaccine Candidate, VLA1553
VLA1553 has been assigned a Prescription Drug User Fee Act (PDUFA) review goal date at the end of August 2023.